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Transcriptional regulationJun dimerization protein 2 (JDP2) is a repressor of transcription factor AP-1. To investigate the transcrip-
tional regulation of the JDP2 gene, we cloned the 50-ﬂanking region of the mouse JDP2 gene. Primer
extension analysis revealed a new transcription start site (+1). Promoter analysis showed that the region
from nt 343 to nt +177 contains basal transcriptional activity. Interestingly, the tumor suppressor p53
signiﬁcantly repressed the transcriptional activity of the JDP2 promoter. Given that JDP2 inhibits expres-
sion of p53, our results suggest a negative feedback loop between JDP2 and p53, and a direct link between
JDP2 and a key oncogenic pathway.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The mammalian activating protein-1 (AP-1) proteins are
homodimers or heterodimers composed of basic region-leucine
zipper (bZIP) proteins that belong to the Jun (c-Jun, Jun B, and
Jun D), Fos (c-Fos, Fos B, Fra-1, and Fra-2), and the closely related
activating transcription factor (ATF2, LRF1/ATF3, and B-ATF) sub-
families [1]. Jun dimerization protein 2 (JDP2) was initially iso-
lated based on its ability to interact with the c-Jun bZIP domain
[1]. JDP2 can homodimerize or heterodimerize with other Jun
family members and with ATF2, but not with c-Fos [1–4]. As a
transcription factor, JDP2 binds both the TPA response element
and cAMP response element to counteract an AP-1 activity
[1,3]. Therefore, JDP2 functions as an AP-1 repressor to inhibit
the AP-1 targeting gene expression.
JDP2 plays critical roles in many cellular processes including
differentiation, apoptosis, antioxidant processes, senescence, cell
cycle, and aging [5,6]. The role of JDP2 in tumor development is
complex. Several studies have shown that JDP2 regulates of several
key cancer-related genes including p53 [5,7–11]. JDP2 exerts its
inhibitory role in ultraviolet-induced apoptosis by downregulating
p53 [12]. The repression of p53 induction by JDP2 is mediated viaan AP-1-like site in the p53 promoter, which differs from the con-
sensus AP-1 site by a single base pair substitution. This motif,
termed PF-1, also modulates p53 promoter activity in response
to serum growth factors and can confer transcriptional repression
on a heterologous promoter. Van der Weyden et al. recently
reported that JDP2 transcriptionally downregulates the p53 pro-
moter via an atypical AP-1 site and that JDP2 negatively regulates
p53 transcription to promote mouse leukemogenesis in the con-
text of p53 heterozygosity [10].
We have reported that JDP2 expression is downregulated in
pancreatic carcinoma [13] and that JDP2 inhibits the epithelial-
to-mesenchymal transition (EMT) in pancreatic cells [7,14], sug-
gesting that JDP2 acts as a tumor suppressor. Heinrich et al. found
that JDP2 inhibits Ras-induced transformation of NIH3T3 cells and
represses formation of tumor xenografts of prostate cancer cells in
mice [15]. However, virus insertional mutagenesis analysis has
identiﬁed JDP2 as an oncogene in mouse lymphoma. JDP2-trans-
genic mice display potentiation of liver cancer [16–18]. In either
case, it is important to determine how JDP2 expression is
regulated.
In this study, we have cloned the genomic DNA which
contained the mouse JDP2 promoter and characterized its JDP2
promoter region. We show that p53 represses the activity of a
reporter gene whose transcription is driven by the 50-regulatory
region of the JDP2 gene, suggesting a negative feedback link
between JDP2 and p53 tumor suppression.
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2.1. Isolation of murine JDP2 genomic clones and sequence analysis
A 129/SvJ mouse liver-derived genomic library, constructed in a
lambda FIX II vector (Stratagene, La Jolla, CA, USA), was screened
with the full-length cDNA of murine JDP2 (accession number NM-
030807) as a probe. The probe was labeled using a Random Primer
DNA labeling kit (F. Hoffman-La Roche Ltd., Basel, Switzerland).
Two positive clones (#12 and #17) were isolated from 106 plaques
and conﬁrmed by Southern hybridization. Southern blotting was
performed as described previously [3]. Both clones were digested
withNotI to release their inserts and then subcloned into the pBlue-
script II KS vector (Stratagene). Mapping and sequencing demon-
strated that only the 50-ﬂanking region, noncoding exon 1, and
most of intron 1 were included in both lambda phage clones.
2.2. Primer extension assays
A JDP2-speciﬁc antisense oligonucleotide (50-CTGATGTGCCT
GACGGGATC-30) complementary to nucleotide (nt) 80–99 of the
previously published cDNA sequence [3] was used as the primer.
Full details are provided in the Supplementary data.
2.3. Plasmids
The reporter constructs were made using a promoterless Fireﬂy
luciferase reporter vector pGL3-basic (Promega, Madison, WI,
USA). A 4.4 kb fragment obtained from phage clone #12 was sub-
cloned into the BglII site of the pGL3-basic vector, generating the
pGL34400/+177 vector. Six deletion constructs were produced
by digestion of the pGL34400/+177 plasmid with the restriction
enzymes XhoI (pGL33600/+177), SacI (pGL31192/+177), and
SmaI (pGL31192/+177D921/343 and pGL3343/+177) fol-
lowed by self-ligation. Two other deletion constructs (pGL3896/
+177 and pGL3491/+177) were generated in two steps.
pGL31192/+177 was originally digested with BamHI and partially
with NotI, and the resulting two fragments were ligated into the
BamHI–NotI site of the pBluescript II KS. Both of fragments were
cut out again with SacI and BamHI, and were then ligated into
the SacI–BglII site of the pGL3-basic vector. pGL3557/+177 was
constructed using a PCR-based method. The primers mJDP2-PF4
(50-TAGCTAGCTATATAGCCGGGGCTAATGC-30) and J3R (50-CTGA
TGTGCCTGACGGGATC-30) were used to amplify the desired frag-
ment. The PCR products were then digested with NheI and BamHI,
and then ligated to the pGL3-basic vector that had been digested
with NheI and BglII. All resulting constructs were conﬁrmed by
sequencing analysis. The expression vectors for the wild-type
p53 (pCAG-wt-p53) and a mutant p53 (pCAG-MTp53 R273H) were
constructed as described elsewhere [19].
2.4. Cells
F9 mouse teratocarcinoma cells were maintained in Dulbecco’s
modiﬁed Eagle’s medium with 10% fetal bovine serum (FBS) (Life
Technologies). H358 non-small-cell lung carcinoma cells with a
p53-null mutation were cultured in RPMI 1640 medium with
10% FBS. HCT116 colon adenocarcinoma cells, which were wild
type and homozygous for disruption of the p53 gene, were kindly
provided by Dr. Bert Vogelstein (John Hopkins University, USA) and
grown in McCoy’s 5A modiﬁed medium supplemented with 10%
FBS (Life Technologies).
2.5. Transfection and luciferase assays
The cells were transiently transfected in six-well plates at
50–80% conﬂuence with Lipofectamine2000 reagent (LifeTechnologies) according to the manufacturer’s protocol. Luciferase
activities in cell lysates were measured using the Dual Luciferase
Assay system (Promega). A Renilla luciferase expression plasmid,
pRL-TK, was used as an internal control of transfection efﬁciency.
The values of Fireﬂy luciferase in each samples were normalized
by that of Renilla luciferase in order to obtain the relative luciferase
activity. The results were presented as fold inductions, which was
calculated by dividing, the normalized relative luciferase activity in
transfected cells compared with that of the control cells.3. Results
3.1. Isolation and sequence analysis of 50-upstream region of murine
JDP2 in genomic clones
To analyze the transcriptional regulation of JDP2, we cloned
50-upstream of the JDP2 gene by screening the recombinant
lambda phages from a mouse strain 129/SvJ genomic library
using JDP2 cDNA as a probe. Two positive clones (Clones #12
and #17) were isolated by the screening, and both clones con-
tained the JDP2 sequence as conﬁrmed by Southern blot analysis
(Fig. 1A). Further sequence analysis indicated that the insert of
clone #17 (12 kb in length) overlapped completely with that
of clone #12 (15 kb in length) (Fig. 1B). We used clone #12 to
characterize further the genomic structure of the JDP2 gene. We
obtained an 11 kb genomic sequence from clone #12 by sequenc-
ing. A comparison of the obtained 11 kb sequence with the nucle-
otide sequence of JDP2 cDNA showed that only the ﬁrst 115 bp
sequence, immediately upstream of the start codon of JDP2 cDNA,
was included in this genomic sequence (Fig. 1B). Next, we per-
formed a BLAST search with the full-length sequence of clone
#12 in the mouse genome database. Our search results revealed
that the genomic sequence we cloned contained the 50-upstream
region, noncoding exon 1, and most of intron 1 of the JDP2 gene
(Fig. 1B).3.2. Mapping of the transcription initiation site by primer extension
The transcription initiation site(s) of the murine JDP2 gene were
deﬁned by primer extension analysis performed with an end-
labeled synthetic oligonucleotide complementary to bases 80–99
of the 50-untranslated region (UTR) present in the JDP2 cDNA. In
the presence of total RNA isolated from F9 cells, several extended
products were observed. None of these bands was detectable in
the control lane containing the yeast tRNA (data not shown). The
major fragment corresponded to a major transcription initiation
site located 95 bp upstream of the ﬁrst nucleotide of previously
published JDP cDNA [3]. This was deﬁned as nucleotide +1 of
JDP2 mRNA. The exact position of the new transcription start site
with respect to the sequence of the JDP2 50-UTR region is indicated
in Fig. 2B.
We were unable to ﬁnd the typical putative promoter elements
that include a TATA box, CCAAT box, or GC-box within the
upstream region of the major transcription initiation site. How-
ever, computer analysis revealed that this region contained a high
GC content and multiple putative regulatory elements (Fig. 2B).
Some TATA-less core promoters contain an initiator (Inr) and
downstream promoter element (DPE) [20,21]. The general
sequences of the Inr and DPE are YYANWYY (C/T C/T A N A/T C/T
C/T) and RGWYV(T) (A/G G A/T C/T A/C/G (T)), respectively.
Fig. 2B shows an Inr around the +1 site and a DPE sequence down-
stream from the transcription start site. These data suggest that the
+1 site corresponding to position 85,599,923 on mouse chromo-
some 12 is very likely a novel transcription start site of the JDP2
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Fig. 1. Isolation of murine JDP2 genomic clones. (A) A 129/SvJ mouse liver-derived genomic library was screened with the full-length cDNA of murine JDP2 as a probe. Two
positive clones (#12 and #17) were isolated and conﬁrmed by Southern blotting. (B) The inserts from both clones were released by digestion, subcloned into the pBluescript II
KS vector, and sequenced. Mapping and sequencing demonstrated that the 50-ﬂanking region (crossed box), noncoding exon 1, and most of intron 1 of the JDP2 gene were
included in the 11-kb insert (hatched box). The genomic locations of each exon in mouse chromosome 12 are presented (Exon I, II, III and IV). Exons (light gray boxes) and the
1st intron (gray box) were indicated. The location of the newly identiﬁed transcription initiation site (85,599,923) is shown.




























































   +1  Inr                                             DPE
GCCCCAGACCTGCTGACAGGTCGCGCCTCAGCCTCTTCCGTAGCTCTCTTTGCAAGACCTGGAGGGGAGG                          
GTATTGAGAAAGGCATCTAACCAACAGGGCTTCCTTCGCTTAAGAGCATTGCTGCGGCGGGCTCTGGCTG
                                     +177 (85,600,098)
GGTTAGGAGGGAACCACGGGGCAGTCCCCAGTTCCTTGG-3’ 
5’-  
Fig. 2. Identiﬁcation of the new transcription initiation site. (A) Primer extension assays were performed using total RNA isolated from F9 cells and an end-labeled JDP2-
speciﬁc antisense oligonucleotide. The extension products were separated on a polyacrylamide gel, dried and subjected to autoradiography. A genomic sequencing ladder was
created with the same primer to identify the genomic location of transcription initiation site (arrow). (B) The nucleotide sequence of the 50-upstream region of the mouse
JDP2 gene. The numbers represent the nucleotide position relative to the newly identiﬁed transcription initiation site (+1). The initiator sequence (Inr) and downstream
promoter element (DPE), the sequences frequently seen within TATA-less core promoters, are underlined. The p53-responsive region is double underlined. The putative p53-
binding site is boxed.
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To identify the promoter region, we subcloned the JDP2 50-
upstream promoter sequence (4.4 kb to +177 bp) and a series of
deleted sequences into the upstream of a ﬁreﬂy luciferase reporter
gene in a pGL3-basic vector (Fig. 3). All the constructs were tran-
siently transfected into F9 cells, and a dual luciferase assay was
performed 24 h after transfection. Transfection of the 4400/
+177 and 3800/+177 constructs resulted in a 7.5- and 11-fold
increases in luciferase activity, respectively, compared with the
promoter-less pGL3-basic construct, whereas the 1192/+177 con-
struct increased luciferase expression by about 15-fold (Fig. 3A).
These ﬁnding suggest that the promoter region lies between
1192 and +177 and that the region between 4400 and 1192
may contain negative regulatory element(s). Moreover, the lucifer-
ase activities of pGL3896/+177 and pGL3557/+177 were
29- and 15-fold, respectively, compared with the empty vector
pGL3-basic. These results indicate the presence of negative and
positive regulatory elements in the 896/557 sequence and the1192/896 sequence, respectively. Further deletions to 491
and 343 decreased the luciferase activity. However, a 3.5-fold
increase in luciferase activity was observed when the deletion
was extended to 343. Thus, the basal promoter activity resides
in the 343 to +177 region, which lacks the TATA sequence but
contains the Inr and DPE core promoter structure.
Yao et al. recently reported that the sequence 261 to +54 of
the JDP2 gene, which corresponds to 767 to 452 in our study,
is required for the basal promoter activity of the JDP2 gene [22].
This region contains another transcription start site located
507 bp upstream from +1, as shown in Fig. 2B. In agreement with
this report, deletion of the sequence between 921 and 343 in
the pGL31192/+177 construct markedly reduced the luciferase
expression (Fig. 3C). Moreover, the 30-deleted construct
pGL3557/302 showed full promoter activity (Fig. 3C), indicating
that the region between 557 and 452 contains a promoter, that
is independent of the promoter located between 343 and +177.
Importantly, the pGL31192/+177921/343 construct retained
luciferase expression, which was about 2.5-fold higher compared
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moter region lies between 343 and +177.3.4. Transcriptional repression of the JDP2 promoter by p53
To identify transcription factors that might regulate JDP2 tran-
scription, we searched putative transcription factor-binding sites
within the sequence 1192 to +177 using PROMO software. Inter-
estingly, multiple potential p53-binding sites were observed in 50-
upstream promoter region. To determine whether p53 plays a role
in JDP2 gene regulation, we assessed H358 non-small-cell lung car-
cinoma cells with a p53-null mutation and HCT116 colon adeno-
carcinoma cells homozygous for disruptions of the p53 gene.
Both cell lines were transiently transfected with the full-length
JDP2 promoter construct (pGL31192/+177) and a wt-p53 cDNA
expression vector. As shown in Fig. 4A. wt-p53 reduced the activity
of the JDP2 promoter by 6–7-fold in H358 cells. A similar level of
repression by p53 was observed in the HCT116 p53-null cells
(Fig. 4A, right panel). In the same experiments, a mutant p53,
p53R273H, also inhibited the JDP2 promoter activity to some
extent, although the level of repression was weaker than that by
wt-p53 in both cell lines. In addition, with increasing amounts of
the wt-p53 expression vector, a dose-dependent decrease in JDP2
promoter activity was observed in both cell lines (Fig. 4B). Thus,










































Fig. 3. Characterization of the JDP2 gene promoter region. (A) pGL3-basic and JDP2
50-upstream region constructs (4400/+177, 3600/+177, and 1192/+177) con-
taining the luciferase gene were prepared and used in luciferase assays in F9 cells.
(B) A series of sequential deletions were constructed and transfected into F9 cells.
Luciferase assays were performed to identify the JDP2 basal promoter. (C)
Conﬁrmation of another JDP2 promoter recently identiﬁed. The bar graph shows
the relative levels of luciferase activity. The luciferase activity of pGL3-basic was set
to 1. The data shown are the mean ± SD from luciferase assays performed in
triplicate.3.5. Identiﬁcation of the p53-responsive region within the JDP2
promoter
To identify the p53-responsive region within the JDP2 pro-
moter, we cotransfected the pGL3557/302 construct with the
wt-p53 expression vector or empty vector into HCT116 colon ade-
nocarcinoma cells. The pGL3557/302 construct contains a pre-
viously identiﬁed strong promoter [22] (Fig. 3C). As shown in
Fig. 4C, the luciferase activity of pGL3557/302 was markedly
decreased by the ectopic expression of wt-p53 but not by expres-
sion of the empty vector, indicating that the wt-p53 responsive
element lies between 557 and 302. To identify the minimal
p53-responsive region, we made a series of further deletion muta-
tions and transfected them into HCT116 cells. Wt-p53 signiﬁcantly
inhibited luciferase expression when deletion mutants
pGL3D486/421, pGLSD462/384, and pGL3D445/326
were used, suggesting that the sequence between 486 and
326 is not required for wt-p53 reaction. Thus, the essential
p53-responsive region may be located between 557 and 486
or between 326 and 302. A putative p53-binding site in the
550/540 bp region was identiﬁed by prediction of transcription
factor binding by PROMO software (Fig. 2B), suggesting that the
essential p53-responsive region may lie between 557 and 486.4. Discussion
We identiﬁed and characterized the basal promoter for the
mouse JDP2 gene located between nt 343 and +177. We found
that the region between nt 557 and 452 also shows promoter
activity, which is consistent with a very recent observation by
Yao et al. [22]. It has been demonstrated that the start site selection
within many mouse core promoters varies between tissues [23].
Thus, multiple transcription initiation sites might contribute to
the various transcripts of the JDP2 gene found in a number of dif-
ferent mouse tissues [3]. We identiﬁed this new site from embry-
onic carcinoma F9 cells. Multiple transcription initiation sites
could be used to ﬁne-tune JDP2 function at different developmen-
tal stages. In agreement with this hypothesis, a UCSC browser
search showed high levels of histone H3 lysine 4 trimethylation,
a marker of an active promoter, around the new transcription ini-
tiation site in embryo cells but not in other types of cells tested,
supporting the idea that multiple initiation sites are used for tis-
sue-speciﬁc expression of this gene.
Here, we found that wt-p53 repressed the JDP2 promoter in
both H358 and HCT116 p53-null cell lines (Fig. 4). Other studies
have shown that expression of wt-p53 reduces the activity of a
variety of promoters, including those of the Fos, c-Jun genes [24].
Thus, p53 seems to display a broad type of repression of the pro-
moters of AP-1 members including JDP2. The signiﬁcance of the
downregulation by p53 of these molecules with distinct functions
deserves further investigation. In this study, we also found that
mutant p53 resulted in the repression of the JDP2 promoter activ-
ity. One possible reason is that the mutant that we used contains
only one point mutation in the DNA binding domain (R273H) of
p53. Because some studies have shown that the transcriptional
repression by p53 is also related to the other functional portions
of p53 in addition to the DNA-binding domain, the R273H muta-
tion could not completely abolish the function of transcriptional
repression by p53. There is growing evidence that mutant p53s
have gained functions that promote malignant progression [24–
27]. The repression of JDP2 expression, a general inhibitor of AP1,
may represent one gain of function of the R273H p53 mutant.
We reported that JDP2 represses epithelial–mesenchymal transi-
tion (EMT) in pancreatic cells [7,13,14]. Intriguingly, Zhang et al.
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Fig. 4. Regulation of the JDP2 gene promoter by p53. (A) pGL31172/+177 was cotransfected with the pCAG empty vector, wt-p53 or p53R273H mutant plasmid into two
different p53-null cell lines, and luciferase expression was measured. The bar graph shows the relative levels of luciferase activity normalized to empty vector control. The
data shown are the mean ± SD from luciferase assays performed in triplicate. (B) Dose-dependent repression of the JDP2 promoter activity by wt-p53. Increasing amounts of
wt-p53 plasmid was cotransfected with the pGL31192/+177 luciferase reporter gene into HCT116 p53 null cells, and luciferase assays were performed in triplicate. The data
shown are the mean ± SD. (C) Identiﬁcation of the p53-responsive region. The JDP2 promoter reporter (1192/+177 and 557/302) and different internally deleted
promoters as indicated (557/302) were used to transfect F9 cells. The blue bars represent luciferase expression in the control (empty vector) cells. The red bars indicate
luciferase expression in wt-p53-transfected cells. Luc; luciferase. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of
this article.)
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tion of JDP2 expression may contribute to the p53 mutant gain of
function such as during the EMT. It would be interesting to
determine whether other p53 mutants also downregulate JDP2
expression and, if so, what impact these p53 mutants have on
the EMT.
Unlike the activation of gene expression, the mechanism of
repression by wt-p53 is not well deﬁned, and p53 has been shown
to repress transcription by different mechanisms [28]. These mech-
anisms include: (1) binding of p53 to TATA-binding proteins; (2)
recruitment of mSin3a and histone deacetylases by p53 to the gene
promoter; (3) sequence-speciﬁc DNA binding of p53 to the consen-
sus sequence present in the regulatory region of genes; and (4)
interactions of p53 with other cis-acting elements, including SP-
1, CCAAT, and AP-1. The 50-ﬂanking sequence of the JDP2 gene is
TATA-less and contains potential p53-binding sites and several
SP-1 binding sites. In the future, we will determine which motif
within the JDP2 promoter is responsible for the regulation of
JDP2 transcription by p53.
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